StockNews.AI
LUNG
StockNews.AI
4 hrs

Pulmonx Reports Third Quarter 2025 Financial Results

1. Pulmonx reported Q3 2025 revenue of $21.5 million, a 5% year-over-year increase. 2. International revenue reached $7.5 million, growing 15% year-over-year. 3. U.S. revenue was $14.0 million, up 1% from the prior year. 4. Gross margin improved to 75%, up from 74% last year. 5. The company updates 2025 revenue outlook to $89-$90 million.

15m saved
Insight
Article

FAQ

Why Bullish?

The slight revenue increase and improved margins are positive signals. Historically, consistent revenue growth often leads to upward price movement in stocks.

How important is it?

The financial performance and guidance updates are crucial for investor sentiment and stock valuation.

Why Short Term?

Recent financial results can impact LUNG’s stock price soon, as investors react to earnings reports quickly.

Related Companies

AVTXBYSITHMO
November 12, 2025 16:05 ET  | Source: Pulmonx Corporation REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in international revenue in the third quarter of 2025, representing 15% year-over-year growth and an increase of 9% on a constant currency basisDelivered $14.0 million in U.S. revenue in the third quarter of 2025, representing 1% year-over-year growthRealized gross margin of 75% in the third quarter of 2025Reappointed Glen French as President and Chief Executive Officer and appointed Derrick Sung as Chief Operating Officer and Chief Financial Officer “While our third quarter performance broadly met expectations, we feel there is a meaningful opportunity to leverage our operational foundation and refine execution to expand Zephyr Valve treatment volumes,” said Glen French, President and Chief Executive Officer of Pulmonx. “We remain steadfast in our mission to improve the quality of life for patients with severe emphysema and are committed to acting with discipline to ensure our investments and operations are aligned with our goal to achieve sustainable, profitable growth.” Third Quarter 2025 Financial ResultsTotal worldwide revenue in the third quarter of 2025 was $21.5 million, a 5% increase from $20.4 million in the third quarter of 2024, and an increase of 4% on a constant currency basis. U.S. revenue was $14.0 million, a 1% increase from the third quarter of 2024. International revenue was $7.5 million, a 15% increase compared to the third quarter of 2024, and a 9% increase on a constant currency basis. The growth in revenue reflects continued commercial execution and global adoption of Zephyr Valve procedures. Gross profit in the third quarter of 2025 was $16.1 million, compared to $15.0 million for the third quarter of 2024. Gross margin for the third quarter of 2025 was 75%, compared to 74% for the same period in 2024. Operating expenses in the third quarter of 2025 were $30.4 million, compared to $29.2 million for the third quarter of 2024, representing an increase of 4%. The increase in operating expenses was attributable to increases in clinical, development, and commercial investments. Net loss in the third quarter of 2025 was $14.0 million, or $0.34 per share, compared to a net loss of $14.1 million, or $0.36 per share for the same period in 2024. Adjusted EBITDA loss in the third quarter of 2025 was $8.2 million compared to $8.1 million for the same period in 2024. Cash and cash equivalents totaled $76.5 million as of September 30, 2025. 2025 Financial OutlookPulmonx is updating its 2025 financial outlook and expects full year 2025 total revenue to be in the range of $89 million to $90 million. The Company expects gross margin for the full year 2025 to be approximately 73%. Pulmonx expects total operating expenses for the full year 2025 to fall within the range of $125 million to $126 million, inclusive of approximately $21 million of non-cash stock-based compensation. The Company’s updated guidance does not anticipate any potential impact from future tariffs or trade policy changes, or their effects on the global macroeconomic environment, including foreign currency fluctuations. Webcast and Conference Call DetailsPulmonx will host a conference call today, November 12, 2025, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter financial results. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call. Use of Non-GAAP Financial MeasuresTo supplement Pulmonx’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, Pulmonx provides certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx’s business. Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management's financial and operational decision-making, including evaluation of Pulmonx’s historical operating results. The Company defines Adjusted EBITDA as earnings before interest income or expense, taxes, depreciation and amortization and stock-based compensation and may also exclude certain non-recurring, irregular or one-time items not reflective of our ongoing core business operations, such as impairment charges. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. Further, management uses adjusted EBITDA for strategic and annual operating planning. We believe these non-GAAP financial measures are useful as a supplement in evaluating our ongoing operational performance and enhancing an overall understanding of our past financial performance. Reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is set forth in the tables below. The non-GAAP financial measures used by Pulmonx should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's consolidated financial statements and publicly filed reports in their entirety. The Company's definition of non-GAAP measures may differ from similarly titled measures used by others. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our possible or assumed future results of operations, including long-term outlook, descriptions of our revenues, total operating expenses, gross margin, profitability, guidance for full year 2025, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), including the Quarterly Report on Form 10-Q filed with the SEC on August 1, 2025, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.  About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTrax™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com. Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation. Investor ContactBrian Johnston Laine MorganGilmartin Groupinvestors@pulmonx.com Pulmonx CorporationConsolidated Statements of Operations(in thousands, except share and per share data)(Unaudited)       Three Months Ended September 30, Nine Months Ended September 30,   2025   2024   2025   2024 Revenue $21,502  $20,387  $67,899  $60,024 Cost of goods sold  5,450   5,361   18,301   15,613 Gross profit  16,052   15,026   49,598   44,411 Operating expenses        Research and development  4,846   3,744   14,908   13,569 Selling, general and administrative  25,599   25,411   78,450   75,129 Total operating expenses  30,445   29,155   93,358   88,698 Loss from operations  (14,393)  (14,129)  (43,760)  (44,287)Interest income  611   1,269   2,198   4,016 Interest expense  (805)  (891)  (2,385)  (2,665)Other income (expense), net  758   (201)  809   179 Net loss before tax  (13,829)  (13,952)  (43,138)  (42,757)Income tax expense  128   192   440   462 Net loss $(13,957) $(14,144) $(43,578) $(43,219)Net loss per share attributable to common stockholders, basic and diluted $(0.34) $(0.36) $(1.08) $(1.11)Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted  40,936,896   39,276,447   40,444,001   38,953,032  Pulmonx CorporationCondensed Consolidated Balance Sheets(in thousands)(Unaudited)     September 30, 2025 December 31, 2024Assets   Current assets   Cash and cash equivalents$76,549  $70,905 Restricted cash 261   257 Short-term marketable securities —   30,577 Accounts receivable, net 13,797   13,120 Inventory 16,248   16,915 Prepaid expenses and other current assets 4,380   4,474 Total current assets 111,235   136,248 Long-term inventory 2,474   1,681 Property and equipment, net 2,443   2,907 Goodwill 2,333   2,333 Right of use assets 18,279   18,545 Other long-term assets 1,517   1,136 Total assets$138,281  $162,850 Liabilities and Stockholders' Equity   Current liabilities   Accounts payable$6,420  $3,827 Accrued liabilities 14,936   16,472 Income taxes payable 189   49 Deferred revenue 92   135 Short-term debt 105   3,176 Current lease liabilities 1,136   778 Total current liabilities 22,878   24,437 Deferred tax liability 47   87 Long-term lease liabilities 18,298   18,515 Long-term debt 37,025   34,002 Total liabilities 78,248   77,041 Stockholders' equity   Common stock 41   40 Additional paid-in capital 568,887   551,211 Accumulated other comprehensive income 2,238   2,113 Accumulated deficit (511,133)  (467,555)Total stockholders' equity 60,033   85,809 Total liabilities and stockholders' equity$138,281  $162,850  Pulmonx CorporationReconciliation of Reported Revenue % Change to Constant Currency Revenue % Change(in thousands)(Unaudited)         Three Months Ended September 30,       2025 2024 % Change FX Impact % Constant Currency % ChangeUnited States$13,967 $13,836 0.9% —% 0.9%International 7,535  6,551 15.0% 5.9% 9.1%Total$21,502 $20,387 5.5% 1.9% 3.6%  Nine Months Ended September 30,       2025 2024 % Change FX Impact % Constant Currency % ChangeUnited States$42,919 $40,586 5.7% —% 5.7%International 24,980  19,438 28.5% 2.6% 25.9%Total$67,899 $60,024 13.1% 0.8% 12.3% Pulmonx CorporationReconciliation of Net Loss to Non-GAAP Adjusted EBITDA(in thousands)(Unaudited)     Three Months Ended September 30, Nine Months Ended September 30,  2025   2024   2025   2024 GAAP Net loss$(13,957) $(14,144) $(43,578) $(43,219)Depreciation and amortization 246   376   823   1,199 Stock-based compensation 5,166   5,839   16,992   17,432 Impairment of capitalized software development costs —   —   —   1,717 Interest expense (income), net 194   (378)  187   (1,351)Provision for income taxes 128   192   440   462 Adjusted EBITDA$(8,223) $(8,115) $(25,136) $(23,760)

Related News